Resolution of tardive dyskinesia following a switch from long-acting injectable risperidone to aripiprazole

Clinical Psychopharmacology and Neuroscience

Volumn 6, Issue 2, 2008, Pages 75-78

  Kim, Sung Wan ^a,b   Lee, Sam Yeon ^a   Kim, Jae Min ^a,b   Shin, Il Seon ^a,b   Yang, Su Jin ^a,b   Yoon, Jin Sang ^a,b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Aripiprazole; Long acting injectable risperidone; Schizophrenia; Tardive dyskinesia

Indexed keywords

ALPHA TOCOPHEROL; ARIPIPRAZOLE; BROTIZOLAM; RISPERIDONE; ZIPRASIDONE;

ADULT; AGITATION; AKATHISIA; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; DAYTIME SOMNOLENCE; DISEASE EXACERBATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; MUSCLE RIGIDITY; NEUROLOGIC DISEASE; PARKINSONISM; PATIENT COMPLIANCE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP DISORDER; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR;

EID: 52149118037     PISSN: 17381088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington DC: American Psychiatric Press Inc; 1994.
2. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000;152:174-180.
3. Nasrallah HA. Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Ann Clin Psychiatry 2006;18:57-62.
4. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1: "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001;62:841-842.
5. Miller del D, Eudicone JM, Pikalov A, Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J Clin Psychiatry 2007; 68:1901-1906.
6. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry 2003;48:771-772.
7. Witschy JK, Winter AS. Improvement in tardive dyskinesia with aripiprazole use. Can J Psychiatry 2005;50:188.
8. Grant MJ, Baldessarini RJ. Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother 2005;39:1953.
9. Sharma A, Ramaswamy S, Dewan VK. Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatry 2005;7:36.
10. Lykouras L, Rizos E, Gournellis R. Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2007;31: 1535-1536.
11. Rizos E, Douzenis A, Gournellis R, Christodoulou C, Lykouras LP. Tardive dyskinesia in a patient treated with quetiapine. World J Biol Psychiatry 2008. In press.
12. Kantrowitz JT, Srihari VH, Tek C. Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot. J Clin Psychopharmacol 2007;27:525-526.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington DC: US Department of Health, Education, and Welfare 1976:534-537.
14. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004;70:91-100.
15. Gharabawi GM, Bossie CA, Zhu Y, Mao L, Lasser RA. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr Res 2005;77:129-139.
16. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997; 321:105-111.
17. Zhang XY, Zhou DF, Cao LY, Xu CQ, Chen DC, Wu GY. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. J Clin Psychopharmacol 2004;24:83-86.
18. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001;CD000209.
19. Maytal G, Ostacher M, Stern TA. Aripiprazole-related tardive dyskinesia. CNS Spectr 2006;11:435-439.
20. Zaidi SH, Faruqui RA. Aripiprazole associated with early onset of tardive dyskinesia like presentation in a patient with ABI and psychosis. Brain Inj 2008;22:99-102.